Immunome (IMNM)
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and oth...
- Open
- 27.100
- High
- 27.690
- Low
- 26.760
- Prev. Close
- 27.400
- Volume
- 965.34K
- Turnover
- 26.39M
- Avg Price
- 27.335
- Bid/Ask Ratio
- 98.02%
- Amplitude
- 3.39%
- 52wk High
- 28.620
- Volume Ratio
- 1.12
- Turnover Ratio
- 0.89%
Immunome Analyst Rating
View moreForecast & Rating
Aug 13, 2026Price forecast
$36.3131.74%
Forecast & RatingStrong buy
14analysts
- Strong buy78.57%
- Buy21.43%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 12 at 06:22 PM
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares
- PUBT · Aug 12 at 04:48 PM
Immunome director Isaac Barchas reports disposal of common shares worth $2.18 million
- Tip Ranks · Aug 12 at 09:05 AM
Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
- Earnings Watch · Aug 11 at 03:12 PM
Immunome | 8-K: FY2026 Q2 Revenue: USD 0
- StockTitan · Aug 11 at 07:02 AM
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update | IMNM Stock News
- Simplywall · Aug 11 at 02:39 AM
Immunome (IMNM) Starts IM 3050 Trial As Valuation Questions Come Into View
